The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Measured by its binding ability in a functional ELISA. When Recombinant Human Apolipoprotein E3 is immobilized at 1 µg/ml (100 µl/well), the concentration of Recombinant Human VLDLR that produces 50% of the optimal binding response is found to be approximately 0.03 - 0.15 µg/ml.
< 1.000 Eu/µg
>95% by SDS-PAGE .
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at 4°C prior to reconstitution. Store at -80°C. Avoid freeze / thaw cycle.
pH: 7.40 Constituents: 95% PBS, 5% Trehalose
This product is an active protein and may elicit a biological response in vivo, handle with caution.
It is recommended to reconstitute ab155621 in sterile PBS to a final concentration of 50 µg/ml. Solubilize for 30 to 60 minutes at room temperature with occasional gentle mixing. Carrier protein (0.1% HSA or BSA) is strongly recommended for further dilution and long term storage. Avoid vigorous shaking or vortexing.
Very low density lipoprotein receptor
Very low-density lipoprotein receptor
Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation.
Abundant in heart and skeletal muscle; also ovary and kidney; not in liver.
Involvement in disease
Defects in VLDLR are the cause of cerebellar ataxia mental retardation and dysequilibrium syndrome type 1 (CMARQ1) [MIM:224050]; also known as dysequilibrium syndrome (DES) or non-progressive cerebellar disorder with mental retardation. CMARQ1 is a congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, mental retardation and cerebellar hypoplasia. Additional features include short stature, strabismus, pes planus and, rarely, seizures.
Contains 3 EGF-like domains. Contains 8 LDL-receptor class A domains. Contains 6 LDL-receptor class B repeats.
Ubiquitinated at Lys-839 by MYLIP leading to degradation.